NCT06474676View on ClinicalTrials.gov

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2032

Conditions
Metastatic Soft-tissue Sarcoma
Interventions
DRUG

Cyclophosphamide

Given by IV

DRUG

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER